



Blastomycosis hospitalizations in northwestern Ontario: 2006–2015

S Litvinjenko^{1*}, D Lunny²

Abstract

Background: Blastomycosis, caused by the organism *Blastomyces dermatitidis*, is an invasive fungal disease found in Central Canada and Central and Midwestern United States.

Objective: To describe trends in and epidemiology of hospitalized cases of blastomycosis reported among northwestern Ontario residents between 2006 and 2015.

Methods: Blastomycosis hospitalization data were extracted from the Discharge Abstract Database (DAD), accessed through IntelliHEALTH Ontario. The DAD includes administrative, clinical and demographic information on hospital discharges provided by the Canadian Institute for Health Information (CIHI). Blastomycosis records were identified using ICD-10 codes B40.0 to B40.9. Hospitalization rates were calculated for all of Ontario, and age-specific hospitalization rates were calculated for northwestern Ontario and analyzed by local health region, time and seasonality as well as presenting symptoms.

Results: There were 581 hospitalizations for blastomycosis reported in Ontario over this 10-year period. Of these, 245 (42%) were from northwestern Ontario, although this region accounts for only 0.6% of the Ontario population. The average hospitalization rate for blastomycosis in northwestern Ontario was 35.0 per 100,000 per year. This rate varied from 1.7 in the Red Lake region to 57.9 in the Kenora region. The most common presentation was acute pulmonary symptoms. Men were 1.36 times more likely to be hospitalized for blastomycosis than were women (95% confidence interval [CI]: 1.06–1.75, $P < 0.05$). Most hospitalizations were registered in the late fall months, suggesting blastomycosis exposure in the spring/summer season followed by a lengthy incubation period.

Conclusion: Areas of northwestern Ontario have high reported rates of blastomycosis. It is not known to what extent there are regional differences in other states and provinces. Interregional differences may warrant prioritizing strategies for blastomycosis prevention and control as well as additional research and surveillance.

Affiliations

¹ Formerly at the Northwestern Health Unit, Kenora, ON

² Northwestern Health Unit, Kenora, ON

*Correspondence: stefan.litvinjenko@mail.utoronto.ca

Suggested citation: Litvinjenko S, Lunny D. Blastomycosis hospitalizations in northwestern Ontario: 2006–2015. *Can Commun Dis Rep.* 2017;43(10):200-5. <https://doi.org/10.14745/ccdr.v43i10a02>

Introduction

Blastomycosis, caused by the organism *Blastomyces dermatitidis*, is an invasive fungal disease whose only known natural reservoir is in soil. Cases of blastomycosis have occurred mainly across the eastern areas of North America, in the provinces and states that border the Great Lakes (i.e., Ontario, Michigan, Wisconsin, Minnesota), but some have also been found in the midwestern United States and central Canada (1). Rarely have cases been reported outside North America.

Symptomatic disease is thought to occur in approximately 50% of cases (2), suggesting that healthy individuals are fairly resistant to the harmful progression of the invasive fungus. It is estimated that 70% of cases can be attributed to pulmonary blastomycosis, which usually presents as flu-like illness; the symptoms may be commonly misdiagnosed as other morbidities, for example, tuberculosis. Extrapulmonary disease most commonly manifests as cutaneous blastomycosis, but it can also occur in the skeletal, urogenital and central nervous systems. With appropriate antifungal and/or surgical treatment, the mortality rate of blastomycosis is between 5 to 10% (2).

The average incubation period of blastomycosis is generally accepted to be 30 to 45 days, although the range can be anywhere from 13 to 106 days, depending on inoculum size (3) and the form of the disease (4). Although blastomycosis infection occurs primarily through the inhalation of airborne spores, it can also occur, though rarely, through a puncture in the skin with infected material. Exposure to the fungal spores may increase during excavation and construction operations as well as during recreational activities that involve contact with soil near waterways as the moist and acidic soil environment is favourable to *B. dermatitidis* growth (2,5). Aerosolization of spores occurs more readily from dry soil that is disturbed (2). Due to changing climatic conditions (i.e., rainfall, temperature and humidity) and the effects on soil composition (i.e., pH and organic content), isolating *B. dermatitidis* from the environment can be challenging (2,3,6).

In Ontario, blastomycosis has not been on the list of reportable diseases since 1989 (due to limited transmissibility and few cases being reported), although the disease remains notifiable in the



province of Manitoba (7). Blastomycosis is common in the central and midwestern United States (8) and remains a reportable illness in Arkansas, Louisiana, Michigan, Minnesota and Wisconsin (9). According to Health Canada, the annual incidence rate of blastomycosis across Ontario, Quebec, Manitoba and Saskatchewan is 0.62 cases per 100,000 population, with areas that have hospitalization rates of 0.3 to 0.6 cases per 100,000 population (10).

A 2005 study on blastomycosis in northwestern Ontario identified a high annual incidence rate of 17.0 cases per 100,000 population in 1989–2005 (*Mann V, Limerick B, Wiebe L. Northwestern Health Unit blastomycosis cases, 1989 to 2005: preliminary analysis. 2005; Unpublished data*). An earlier study over a shorter period (1997–1999) calculated an annual blastomycosis rate of 117.2 cases per 100,000 at the time of an outbreak in Kenora (11). Along with the rate of 404.9 per 100,000 people living on reserve, these rates are considered exceptionally high (11).

The objective of this study is to utilize hospitalization data from the past decade (2006–2015) to describe recent trends in the epidemiology of blastomycosis hospitalization in northwestern Ontario.

Methods

This analysis focuses on hospitalized cases of blastomycosis in northwestern Ontario. For the purposes of this report, the term “northwestern Ontario” refers to the Northwestern Health Unit (NWHU) catchment area. The NWHU catchment area is one of the 36 public health unit regions in Ontario. It serves a population of just under 82,000 across an area of 171,288 square kilometres (roughly one-fifth the size of the province). The area contains part of the Kenora District and all of the Rainy River District, and this analysis includes Kenora, Dryden, Red Lake, Sioux Lookout, Rainy River, Emo, Fort Frances and Atikokan. These regions include the named municipalities as well as any nearby smaller communities and First Nations reserves. There are 39 recognized First Nations in the NWHU catchment area; some are located around the main municipalities while others are more northern and less easily accessible.

Inclusion criteria

The study sample included hospitalization records for any form of blastomycosis diagnosed in Ontario residents between 2006 and 2015 using ICD-10 codes B40.0 to B40.9 as the primary diagnosis (12).

Location of hospitalizations were based on patients’ residence rather than where they were hospitalized. For example, if a patient from northwestern Ontario was hospitalized in Toronto, the hospitalization would be classified as northwestern Ontario. Hospitalizations that occurred outside of Ontario, however, were not captured in the data and could not be assessed.

Data sources

Blastomycosis hospitalization data were extracted on January 20, 2017 from the Discharge Abstract Database (DAD). The DAD was accessed through IntelliHEALTH Ontario, a knowledge repository operated by the Ministry of Health and Long-Term Care. The DAD includes administrative, clinical and demographic information on hospital discharges provided by the Canadian

Institute for Health Information (CIHI). IntelliHEALTH Ontario is operated by the Ontario Ministry of Health and Long-Term Care.

Population estimates for the NWHU catchment area came from Statistics Canada and were accessed through IntelliHEALTH Ontario.

Hospitalization counts and rates

Counts of blastomycosis hospitalizations for each of Ontario’s 36 public health units were tabulated. From these, hospitalization rates were derived for residents of northwestern Ontario as well as from smaller geographical regions within this area.

Crude and age-specific hospitalization rates were calculated by dividing the number of hospitalizations occurring over the time period by the total person-years at risk, and multiplying the result by 100,000 person-years. A rate displayed in 100,000 person-years indicates the number of hospitalizations that occur in a population of 100,000 people over the course of one year.

Age-standardized hospitalization rates were calculated using the 2011 Canadian Census population as the reference population. All analyses were conducted using Microsoft Excel, Open Epi and EpiInfo7.

Northwestern Ontario rates

Age-standardized hospitalization rates for the population within the NWHU catchment and the subregions within it as well as the corresponding 95% confidence intervals (CIs) were calculated using the Poisson approximation of the normal distribution. Rate ratios were calculated and used to identify any statistical differences in hospitalization rates between the subregions. Results were considered statistically significant if the 95% CI around the rate ratio did not contain one.

Rates by age and sex

Age- and sex-specific hospitalization rates and 95% CIs were calculated using the Mid-P Exact method. Ten-year age groups were used for the analysis (0–9, 10–19, etc.). Tests for statistical differences in rates between age and sex strata were carried out by calculating the rate ratios. Results were considered statistically significant if the 95% CI around the rate ratio did not contain one.

Counts by diagnosis code

Counts of hospitalizations categorized by type of blastomycosis were tabulated for northwestern Ontario. Counts for each type of blastomycosis were based on ICD-10 diagnosis codes, which ranged from B40.0 to B40.9 (12).

Counts by year and month

Counts of hospitalizations were examined by year and month of occurrence. Cumulative month totals over the 10-year study period were calculated to determine when in the year hospitalizations were the most common.

Results


Blastomycosis hospitalizations in Ontario

Between 2006 and 2015, a total of 581 blastomycosis hospitalizations were recorded by 29 of Ontario’s 36 public



health units (the remaining seven health units registered no cases). Notably, 245 blastomycosis hospitalizations (42%) were attributed to residents of northwestern Ontario alone (i.e., in the NWHU) (Figure 1).

Figure 1: Number of blastomycosis hospitalizations by public health unit, Ontario, 2006–2015 (n=581)




Source: Inpatient Discharges 2006–2015. Ontario Ministry of Health and Long-Term Care. IntelliHEALTH Ontario. Date Extracted: January 10, 2017

Hospitalizations in northwestern Ontario by region

In northwestern Ontario, the hospitalization rate for blastomycosis was 35.0 per 100,000 per year between 2006 and 2015. Kenora had the highest rate of hospitalizations, at 57.9 per 100,000 per year, and a statistically significant rate ratio of 3.13 (95% CI: 2.42–4.09; P<0.01) compared with the rest of northwestern Ontario. Due to small counts, hospitalizations in the Atikokan, Emo and Red Lake subregions have been suppressed and are not reported on. Other regions in the area had hospitalizations rates that ranged from 16 to 32 per 100,000 per year (Figure 2).

Figure 2: Blastomycosis hospitalizations* by northwestern Ontario region†, 2006–2015



* Rates per 100,000 per year age standardized, with 95% confidence intervals
† Regions include the named municipality in addition to smaller nearby communities and First Nation reserves
Note: Results from Red Lake, Emo and Atikokan were omitted due to small counts
Source: Inpatient Discharges 2006–2015. Ontario Ministry of Health and Long-Term Care. IntelliHEALTH Ontario. Date Extracted: January 10, 2017


Hospitalizations in northwestern Ontario by age and sex

Males, who represented 50.3% of the population in the NWHU catchment area between 2006 and 2015, accounted for 58%

(n=142) of all blastomycosis hospitalizations (compared with n=103 for females). The rate of blastomycosis hospitalizations for males of all ages was 34.4 per 100,000 per year, compared with 25.3 per 100,000 per year for females. This equals a statistically significant rate ratio of 1.36 (95% CI: 1.06–1.76; P<0.05).

Blastomycosis hospitalizations were lowest among children aged less than 10 years and adults aged 60 years and older. Rates were generally highest among adults in their twenties to their fifties (Figure 3). People in the 30- to 39-year age category had a statistically significant rate ratio of 2.04 (95% CI: 1.49–2.76; P<0.01) compared with the other age categories. However, examination of the data showed that overrepresentation of males inflated this overall estimate; the rate ratio among men aged 30–39 years was 2.51 (95% CI: 1.70–3.66; P<0.01) compared with females in this age group, among whom rates were insignificant.

Figure 3: Blastomycosis hospitalization rates* by age and sex, northwestern Ontario, 2006–2015




*Rates per 100,000 per year with 95% confidence intervals
Source: Inpatient Discharges 2006–2015. Ministry of Health and Long-Term Care. IntelliHEALTH Ontario. Date Extracted: January 10, 2017

Hospitalizations in northwestern Ontario by ICD-10 diagnosis code

The majority of blastomycosis hospitalizations between 2006 and 2015 (75% of total cases), were due to pulmonary illness (Figure 4). While the nature of some cases (~10%) is unspecified, it can be assumed that most would also have been attributed to acute pulmonary infection indicative of temporary infection. This differs from the more infectious relapsing chronic condition, which accounts for 2.5% of known hospitalizations. Other manifestations of blastomycosis disease, including cutaneous and disseminated varieties, accounted for less than 5% of known hospitalizations.

Figure 4: Blastomycosis hospitalizations by ICD-10 diagnosis code, northwestern Ontario, 2006–2015




Source: Inpatient Discharges 2006–2015. Ontario Ministry of Health and Long-Term Care. IntelliHEALTH Ontario. Date Extracted: January 10, 2017



Hospitalizations in northwestern Ontario by year and month

There was a slight increase in the number of blastomycosis hospitalizations in northwestern Ontario between 2006 and 2015 (Figure 5). Aside from the general increasing trend in hospitalization counts, 2009 and 2013 were noted as peak years, both with 41 hospitalizations.


Figure 5: Blastomycosis hospitalizations in northwestern Ontario by year, 2006–2015



Source: Inpatient Discharges 2006–2015. Ontario Ministry of Health and Long-Term Care. IntelliHEALTH Ontario. Date Extracted: January 10, 2017

Between 2006 and 2015, there were more hospitalizations in the late fall to early winter months, on average, than during any other time of the year (Figure 6).

Figure 6: Blastomycosis hospitalizations in northwestern Ontario by month, 2006–2015 (n=245)



Source: Inpatient Discharges 2006–2015. Ontario Ministry of Health and Long-Term Care. IntelliHEALTH Ontario. Date Extracted: January 10, 2017

Discussion

Between 2006 and 2015, almost 600 hospitalizations for blastomycosis were reported in Ontario. Based on 2015 population estimates, northwestern Ontario accounts for only 0.6% of the provincial population and yet over 40% of total hospitalizations over the period of the study. These rates are likely to be an underestimate of the true incidence of blastomycosis, as the literature suggests that only about 50% of people with blastomycosis present clinical symptoms for hospitalization (13). There appeared to be a lot of regional variation even within northwestern Ontario, with certain health regions reporting zero cases over this 10-year period, while the Kenora region consistently demonstrated one of the highest hospitalization rates for blastomycosis in the province, driving regional/provincial estimates of morbidity. Coupled with previously identified estimates from the literature, high rates

in the Kenora region may be due to geological differences compared to eastern and southern parts of northwestern Ontario, which may result in better soil conditions for blastomycosis, although soil types were not tested as part of this study. It is not known whether such regional variations are also characteristic of other Canadian provinces or the United States (US).

Furthermore, our finding of 35.0 per 100,000 per year hospitalization rate for northwestern Ontario remain well above the highest average annual rate reported in any US state but overlaps with some regional data in the US. In Wisconsin, for example, although there was an age-adjusted rate of 2.9 hospitalizations per 100,000 reported for the state (16), there were reports of 10–40 cases per 100,000 in certain Wisconsin counties (17). It should be noted that average annual increases in blastomycosis rates in the northwestern Ontario might be indicative of genuine increases of incidence of the disease, or reflect improved clinical awareness and testing from physicians (12).

That the majority of blastomycosis cases in Ontario in 2006–2015 were male (58%) is consistent with data from other studies. This finding can be attributed to men dominating the types of labour (such as excavation or construction) common in these areas. More men than women may also prefer recreational activities near waterways that favour growth of *B. dermatitidis* (5). The exception was in the 50- to 59-year age group, where 59% of cases were female and 41% male.

Most blastomycosis hospitalizations were in the 30- to 39-year age group. This is in contrast to Manitoba where 50- to 69-year-olds shared the highest incidence rate (2). Similarly, an older report from northwestern Ontario found the highest hospitalization rates among people in the 40- to 59-year age group (Mann V *et al* unpublished data). Irrespective of age and sex, seasonality trends are consistent with exposure in the spring/summer season and an incubation period that would lead to diagnosis in the late fall.

Strengths and limitations

A strength of this study was the quality of the CIHI data in its capacity to detect regional differences in disease and to provide a comprehensive hospitalization-based sample population (a large proportion of blastomycosis literature is based on outbreak-specific reporting). In terms of validity, Public Health Ontario supplied the NWHU with count data of laboratory-confirmed positive cultures of *B. dermatitidis* for the years 2010–2015, which in theory would be a more representative measure of blastomycosis incidence in the region. However, as the hospitalization data yielded numbers comparable to the laboratory-confirmed count data, the hospitalization data were considered an adequate proxy measure for blastomycosis-associated hospitalization in northwestern Ontario.

A limitation of the study is the use of hospitalization records to assess blastomycosis, which can only serve as a proxy for true incidence, given that not everyone can be expected to seek and/or have access to care or be hospitalized if they do seek medical care. In addition, some cases, particularly severe cases, are referred to Winnipeg, Manitoba; as a result they would not be captured as an Ontario case, and may potentially confound incidence rates in Manitoba between locally attributed exposures, and out of province visitations (14). Moreover, while other studies found significantly higher rates of blastomycosis in Indigenous populations (11,14,15), information



on the Indigenous status of the cases was not available in our study population. Future studies assessing individualized case-record data, the monitoring of relevant risk factors (e.g., socio-demographic factors), isolating probable sources of infection, and determining overall rates of incidence would help address some of the limitations of the current study and increase our understanding of this disease.

Conclusion

Areas of northwestern Ontario have high reported rates of blastomycosis. It is not known to what extent there are regional differences in other states and provinces. Interregional differences may warrant prioritizing strategies for blastomycosis surveillance, prevention and control, as well as additional research.

Authors' statement

SL – Conceptualization, Methodology, Formal Analysis, Investigation, Visualization, Writing – original draft, Writing – review and editing, Project administration

DL – Conceptualization, Methodology, Validation, Resources, Data Collection, Writing – review and editing, Supervision, Project administration

Conflict of interest

None.

Acknowledgements

We would like to thank Dr. Kit Young-Hoon, Medical Officer of Health for the Northwestern Health Unit, for her supervision, expertise and validation of this report. An additional thank you to all of those in the field who helped collect these data and who provide care to those with infectious diseases.

Funding

This research was supported by the Northwestern Health Unit.

References

1. Centers for Disease Control & Prevention. Blastomycosis. Atlanta (GA): CDC. <https://www.cdc.gov/fungal/diseases/blastomycosis/> [Accessed 2017 Feb 8].
2. Manitoba Health Communicable Disease Control Unit. Communicable Disease Management Protocol: Blastomycosis. 2015. <https://www.gov.mb.ca/health/publichealth/cdc/protocol/blastomycosis.pdf>
3. Klein BS, Vergeront JM, Weeks RJ, Kumar UN, Mathai G, Varkey B, Kaufman L, Bradsher RW, Stoebig JF, Davis JP. Isolation of *Blastomyces dermatitidis* in soil associated with a large outbreak of blastomycosis in Wisconsin. *N Eng J Med*. 1986;314:529-34. DOI (<http://dx.doi.org/10.1056/NEJM198602273140901>). PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3945290&dopt=Abstract)
4. Gray NA, Baddour LM. Cutaneous inoculation blastomycosis. *Clin Infect Dis*. 2002;34(10):E44-9. DOI (<http://dx.doi.org/10.1086/339957>). PubMed (<https://www.ncbi.nlm.nih.gov/pubmed/11981746?dopt=Abstract>).
5. Klein BS, Vergeront JM, DiSalvo AF, Kaufman L, Davis JP. Two outbreaks of blastomycosis along rivers in Wisconsin: isolation of *Blastomyces dermatitidis* from riverbank soil and evidence of its transmission along waterways *Am Rev Respir Dis*. 1987;136(6):1333-8. DOI (<http://dx.doi.org/10.1164/ajrccm/136.6.1333>). PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3688635&dopt=Abstract).
6. Morris SK, Brophy J, Richardson SE, Summerbell R, Parkin PC, Jamieson F, Limerick B, Wiebe L, Ford-Jones EL. Blastomycosis in Ontario, 1994–2003. *Emerg Infect Dis*. 2006;12(2):274-9. DOI (<http://dx.doi.org/10.3201/eid1202.050849>). PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16494754&dopt=Abstract)
7. Population and Public Health Branch Summary of reportable diseases 1990. Toronto: Communicable Disease Control, Ontario Ministry of Health; 1991.
8. Seitz AE, Adjemian J, Steiner CA, Prevots DR Spatial epidemiology of blastomycosis hospitalizations: detecting clusters and identifying environmental risk factors. *Med Mycol*. 2015 Jun;53(5):447–54. DOI (<http://dx.doi.org/10.1093/mmy/myv014>). PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25908653&dopt=Abstract).
9. Centers for Disease Control & Prevention. Reportable fungal diseases by state. Atlanta (GA): CDC. <https://www.cdc.gov/fungal/fungal-disease-reporting-table.html> [Accessed 2017 Feb 8].
10. Government of Canada. Surveillance of blastomycosis. Ottawa (ON): Health Canada. <https://www.canada.ca/en/public-health/services/diseases/blastomycosis/surveillance-blastomycosis.html> [Accessed 2017 Feb 8].
11. Dwight PJ, Naus M, Sarsfield P, Limerick B. An outbreak of human blastomycosis: the epidemiology of blastomycosis in the Kenora Catchment Region of Ontario, Canada. *Can Commun Dis Rep*. 2000;26(10):82–91. PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10893821&dopt=Abstract).
12. World Health Organization. International statistical classification of diseases and health related problems, 10th revision. Geneva: World Health Organization. 2016.
13. Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG, Kauffman CA; Infectious Diseases Society of America. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2008;46(12):1801–12. DOI (<http://dx.doi.org/10.1086/588300>). PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18462107&dopt=Abstract).



14. Crampton TL, Light RB, Berg GM, Meyers MP, Schroeder GC, Hershfield ES, Embil JM. Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis. 2002;34(10):1310-6. DOI (http://dx.doi.org/10.1086/340049). PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11981725&dopt=Abstract).
15. Dalcin D, Ahmed S. Blastomycosis in northwestern Ontario, 2004 to 2014. Can J Infect Dis Med Microbiol. 2015;26(5):259-62. DOI (http://dx.doi.org/10.1155/2015/468453). PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=26600814&dopt=Abstract).
16. Seitz A, Younes N, Steiner C, Prevots D. Incidence and trends of blastomycosis-associated hospitalizations in the United States. PLoS One. 2014;9(8):e105466. DOI (http://dx.doi.org/10.1371/journal.pone.0105466). PubMed (https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=25126839&dopt=Abstract).
17. Benedict K, Roy M, Chiller T, Davis J. Epidemiologic and Ecologic features of blastomycosis: a review. Curr Fungal Infect Rep. 2012;6(4):327-35. DOI (http://dx.doi.org/10.1007/s12281-012-0110-1).

SPREAD THE WORD ABOUT THE FLU

IS IT A COLD OR THE FLU?

SYMPTOM	COLD	FLU (INFLUENZA)
Fever	Rare	Usual, high fever (101°F/38°C or higher) common, lasts 3-5 days
Headache	Rare	Usual, can be severe
Stiff neck and joints	Sometimes, mild	Usual, often severe
Body aches and pains	Sometimes, mild	Usual, may last 1-2 weeks or more
Extreme fatigue	Usual	Usual, may last 2-3 weeks
Runny nose	Usual	Common
Cough	Usual	Common
Sore throat	Common	Common
Clear nasal discharge	Usual, mild to moderate	Usual, can be severe
Complications	Can lead to sinus, ear, or pneumonia	Can lead to pneumonia and other serious complications, especially in high-risk individuals

CHOICE OF INFLUENZA VACCINE

Recipient by age group	Vaccine types available for use	Comments
Children 6-23 months of age	TV, QIV, AIV	TV, QIV and AIV are authorized for this age group. NACI recommends the use of live attenuated influenza vaccine (LAIV) for children 2-5 years of age, after an informed and adjusted TR should be used.
Children 2-5 years of age	TV, QIV	In children without contraindications to the vaccine, any of the following vaccines can be used: LAIV, QIV or TV.
Children 6-17 years of age	TV, QIV, Quadrivalent LAIV	In children without contraindications to the vaccine, any of the following vaccines can be used: LAIV, QIV or TV. The latter vaccine (LAIV) requires a recommendation for the parental use of LAIV in children and adolescents 2-17 years of age. Given the limited data on efficacy of LAIV in children and the potential for change in immune response due to the problem of circulating strains of influenza B and the risk in TV vaccine, NACI continues to recommend that QIV formulation of choice vaccine be used in children and adolescents 6-17 years of age. LAIV is not available. TV should be used.
Adults 18 years of age and older	TV, QIV, LAIV	LAIV is authorized for use in children with certain health conditions and without contraindications. See the Canadian Immunization Guide Chapter on Influenza and Department of Health Canada Notice for 2017-2018, Section on Contraindications and Precautions Section 6) and Choice of vaccine product for children 2-17 years of age Section 6) for more details.

SEASONAL INFLUENZA VACCINE 2017-2018 EDITION

RECOMMENDATIONS FROM THE NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION (NACI) 2017-2018

WHO SHOULD RECEIVE THE VACCINE?

All individuals 6 months of age and older who do not have contraindications to the vaccine, with a particular focus on:

- All pregnant women
- Adults and children with the following chronic health conditions:
 - cardiac or pulmonary disorders (including bronchopulmonary dysplasia, cystic fibrosis and asthma);
 - diabetes mellitus and other metabolic diseases;
 - severe, immune compromising conditions (due to underlying disease, therapy or both);
 - renal disease;
 - anemia or hemoglobinopathy;
 - neurologic or neurodevelopmental conditions**;
 - modified obesity body mass index (BMI) ≥42;
 - children and adolescents (age 6 months to 18 years) undergoing treatment for long periods with antiplatelet/anti-coagulant, because of the potential increase of Borna's syndrome associated with influenza.
- People of any age who are residents of nursing homes and other chronic care facilities.
- People 50 years of age.
- All children 6 to 59 months of age.
- Indigenous peoples.

PEOPLE AT HIGH RISK OF INFLUENZA-RELATED COMPLICATIONS OR HOSPITALIZATION

PEOPLE CAPABLE OF TRANSMITTING INFLUENZA TO THOSE AT HIGH RISK:

- Health care and other care providers in facilities and community settings who, through their activities, are capable of transmitting influenza to those at high risk of influenza complications.
- Household contacts (adults and children) of individuals at high risk of influenza-related complications (either or not the individual at high risk has been immunized):
 - household contacts of individuals at high risk, as listed in the section above;
 - household contacts of infants <6 months of age as these infants are at high risk of complications from influenza but cannot receive influenza vaccine;
 - members of a household expecting a newborn during the influenza season.
- Those providing regular child care to children <59 months of age, whether on or out of the home.
- Those who provide services within closed or relatively closed settings to persons at high risk (e.g., care on a ship).

OTHERS:

- People who provide essential community services.
- People in direct contact during culling operations with poultry infected with avian influenza.

WHO SHOULD NOT RECEIVE THE VACCINE?

- People who have had an anaphylactic reaction to a previous dose of influenza vaccine, or
- People who have had an anaphylactic reaction to any of the vaccine components, with the exception of egg (due to the Canadian Immunization Guide Chapter on Influenza and Statement on Influenza Vaccine for 2017-2018 Section 1 – Contraindications and precautions).

CO-ADMINISTRATION

All intramuscular influenza vaccines may be given together with or at any time before or after administration of other live attenuated or inactivated vaccines.

Given the lack of data for immune interference, based on expert opinion, NACI recommends that LAIV can also be given together with or at any time before or after the administration of any other live attenuated or inactivated vaccine. NACI recognizes that some vaccine providers may choose to give LAIV and other live vaccines simultaneously or separated by at least 4 weeks to avoid any possibility of immune interference. Alternatively, inactivated influenza vaccine (TV) or quadrivalent inactivated influenza vaccine (QIV) may be given.

LIVE ATTENUATED INFLUENZA VACCINE (LAIV) IS ALSO CONTRAINDICATED FOR:

- Children less than 24 months of age, due to increased risk of wheezing.
- Individuals with severe asthma, as defined as currently on oral or high-dose inhaled glucocorticoids or active wheezing, or those with medically attended wheezing in the 7 days prior to immunization.
- Children and adolescents 2 to 17 years of age currently receiving aspirin or aspirin-containing therapy because of the association of Reye's syndrome with aspirin and wild-type influenza infections. It is recommended that aspirin-containing products in children less than 18 years of age be delayed for four weeks after receipt of LAIV.
- Pregnant women, because it is a live attenuated vaccine and there is a lack of safety data at this time. However, it is not contraindicated in breastfeeding mothers.
- Persons with immune compromising conditions, due to underlying disease, therapy or both, as the vaccine contains the attenuated virus.
- The risk of influenza-related hospitalization increases with length of gestation, i.e., it is higher in the third than in the second trimester.
- Those include neuro-muscular, neurodegenerative, neurodevelopmental conditions and seizure disorders (and, for children, latex allergy), but exclude immune and neurodegenerative conditions without neurological conditions.

CANADA.CA/FLU

FLU RESOURCES FOR HEALTHCARE PROFESSIONAL.

+ Order your free Flu Vaccine Pocket Guide and other flu resources today

+ Available in both official languages

PLACE YOUR ORDER TODAY. VISIT CANADA.CA/FLU